scout
|Videos|December 16, 2017

Dr. O'Reilly Discusses Advancements in Early-Stage Pancreatic Cancer

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early stage pancreatic cancer.

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early-stage pancreatic cancer.

The major change for patients with early-stage pancreatic cancer is the combination of cytotoxic chemotherapy in the adjuvant setting. Data from ESPAC-4 study demonstrated that the addition of capecitabine to gemcitabine had an improvement in overall survival with low toxicity.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME